Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review

Document Type : Original Article

Authors

1 Department of Clinical Sciences, American University of the Caribbean School of Medicine, Cupecoy, Sint Maarten

2 Department of Clinical Sciences, St. George’s University School of Medicine, West Indies, Grenada

3 Department of Clinical Sciences, Ross University School of Medicine, Miramar, Florida, United States

4 Department of Clinical Sciences, St. Matthews University School of Medicine, Orlando, Florida, United States

5 Department of Internal Medicine, River Oaks Treatment Center, Riverview, Florida, United States

10.34172/ahj.1682

Abstract

Background: Opioid use disorder (OUD) is a global health crisis, contributing to significant public health challenges and economic loss. Although existing treatments are available, there is a critical need for novel therapeutic strategies. This review examined the potential of glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used in diabetes management, as a repurposed treatment for OUD.
Methods: We explored preclinical studies that demonstrate how GLP-1 receptor agonists can modulate neurobiological pathways involved in opioid addiction, particularly dopaminergic signaling. We also reviewed initial human clinical trials examining the impact of GLP-1 receptor agonists on opioid self-administration, relapse behavior, and cravings.
Findings: Preclinical data suggest that GLP-1 receptor agonists can reduce opioid self-administration and relapse behavior in animal models. Early human clinical trials indicate promising results, showing a potential role for GLP-1 receptor agonists in reducing opioid cravings and improving treatment outcomes.
Conclusion: Although early findings are encouraging, further research is needed to confirm these results, optimize dosing regimens, and clarify the underlying mechanisms of action. Given the interplay between metabolic and neuropsychiatric factors in OUD, GLP-1 receptor agonists offer a unique therapeutic advantage. Large-scale clinical trials are essential to determine their long-term efficacy, safety, and integration into comprehensive OUD treatment plans.

Highlights

 Skylar Bronson(Google Scholar)(Pubmed)

Keywords

References

  1. Florence C, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350. doi: 10.1016/j. drugalcdep.2020.108350.
  2. American Psychiatric Association. Opioid Use Disorder [Internet]. Available from: https://www.psychiatry.org/patients-families/opioid-use-disorder. Accessed June 19, 2024.
  3. United Nations Office on Drugs and Crime (UNODC). UNODC World Drug Report 2021: Pandemic Effects Ramp up Drug Risks, as Youth Underestimate Cannabis Dangers [Internet]. UNODC; 2021. Available from: https://www. unodc.org/unodc/press/releases/2021/June/unodc-world-drug-report-2021_-pandemic-effects-ramp-up-drug-risks-- as-youth-underestimate-cannabis-dangers.html. Accessed June 19, 2024.
  4. Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(50-51):1445-52. doi: 10.15585/mmwr.mm655051e1.
  1. Spencer MR, Garnett M, Miniño AM. Drug overdose deaths in the United States, 2002-2022. NCHS Data Brief. 2024(491):1- 9. doi: 10.15620/cdc:135849.
  2. Sharma B, Bruner A, Barnett G, Fishman M. Opioid use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):473- 87. doi: 10.1016/j.chc.2016.03.002.
  3. National Institute on Drug Abuse. Drug Overdose Death Rates [Internet]. Available from: https://nida.nih.gov/research-topics/ trends-statistics/overdose-death-rates. Accessed June 19, 2024.
  4. McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797-802. doi: 10.1001/archpediatrics.2012.85.
  5. Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry. 2020;87(1):44-53. doi: 10.1016/j.biopsych.2019.05.023.
  6. Thompson BL, Oscar-Berman M, Kaplan GB. Opioid-induced structural and functional plasticity of medium-spiny neurons in the nucleus accumbens. Neurosci Biobehav Rev. 2021;120:417-30. doi: 10.1016/j.neubiorev.2020.10.015.
  7. Centers for Disease Control and Prevention. Animated Leading Causes [Internet]. Available from: https://wisqars.cdc. gov/animated-leading-causes/. Accessed June 19, 2024.
  8. Barnett ML, Olenski AR, Jena AB. Opioid-prescribing patterns of emergency physicians and risk of long-term use. N Engl J Med. 2017;376(7):663-73. doi: 10.1056/NEJMsa1610524.
  9. Brummett CM, Waljee JF, Goesling J, Moser S, Lin P, Englesbe MJ, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. doi: 10.1001/jamasurg.2017.0504.
  10. National Institute on Drug Abuse, National Institutes of Health, US Department of Health and Human Services. National Institute on Drug Abuse [Internet]. Bethesda, MD: NIDA. Available from: https://nida.nih.gov/. Accessed June 19, 2024.
  11. Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43(13):2514-20. doi: 10.1038/s41386-018-0225-3.
  12. Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82-8. doi: 10.1016/j. biopsych.2019.06.020.
  13. Freet CS, Evans B, Brick TR, Deneke E, Wasserman EJ, Ballard SM, et al. Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder. Addict Sci Clin Pract. 2024;19(1):56. doi: 10.1186/ s13722-024-00481-7.
  14. Bornebusch AB, Fink-Jensen A, Wörtwein G, Seeley RJ, Thomsen M. Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs. eNeuro. 2019;6(2):ENEURO.0443-18.2019. doi: 10.1523/eneuro.0443-18.2019.
  15. Douton JE, Augusto C, Stoltzfus B, Carkaci-Salli N, Vrana KE, Grigson PS. Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats. Behav Pharmacol. 2021;32(4):265-77. doi: 10.1097/ fbp.0000000000000609.
  16. Evans B, Stoltzfus B, Acharya N, Nyland JE, Arnold AC, Freet CS, et al. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. Brain Res Bull. 2022;189:163-73. doi: 10.1016/j.brainresbull.2022.08.022.
  17. Zhang Y, Kahng MW, Elkind JA, Weir VR, Hernandez NS, Stein LM, et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology. 2020;45(3):451-61. doi: 10.1038/s41386-019-0531-4.
  18. Engel JA, Jerlhag E. Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy. CNS Drugs. 2014;28(10):875-86. doi: 10.1007/s40263-014-0178-y.
  19. Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci. 2013;7:181. doi: 10.3389/ fnins.2013.00181.
  20. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013;8(7):e69010. doi: 10.1371/journal.pone.0069010.
  21. Hernandez NS, Ige KY, Mietlicki-Baase EG, Molina-Castro GC, Turner CA, Hayes MR, et al. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology. 2018;43(10):2000-8. doi: 10.1038/s41386-018-0010-3.
  22. Hölscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 2014;10(1 Suppl):S47-54. doi: 10.1016/j. jalz.2013.12.009.
  23. Kinzig KP, D’Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22(23):10470-6. doi: 10.1523/jneurosci.22-23-10470.2002.
  24. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014;9(2):e87366. doi: 10.1371/journal.pone.0087366.
  25. Koob GF. A role for brain stress systems in addiction. Neuron. 2008;59(1):11-34. doi: 10.1016/j.neuron.2008.06.012.
  26. Emery MA, Eitan S. Members of the same pharmacological family are not alike: different opioids, different consequences, hope for the opioid crisis? Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:428-49. doi: 10.1016/j. pnpbp.2019.02.010.
  27. Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384-90. doi: 10.2337/dc22-1148.
  28. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-84. doi: 10.1002/pds.2082.
  29. Jerlhag E. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Front Pharmacol. 2023;14:1063033. doi: 10.3389/fphar.2023.1063033.
  30. Lengsfeld S, Burkard T, Meienberg A, Jeanloz N, Coynel D, Vogt DR, et al. Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study. Trials. 2023;24(1):284. doi: 10.1186/s13063-023-07164-9.
Addiction & Health
Volume 17
Pages 1-7

Files

Share

How to cite

Statistics